Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New stomach acid drug could boost h. pylori cure rates

NCT ID NCT06851468

Disease control Sponsor: Key Laboratory for Gastrointestinal Diseases of Gansu Province Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This completed study tested whether a new drug called keverprazan, combined with the antibiotic amoxicillin, can effectively treat a first-time H. pylori infection in adults. 264 participants took either keverprazan or esomeprazole (a standard acid reducer) plus amoxicillin for 14 days. Researchers measured how many people were cured and tracked side effects.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Keverprazan (a drug that reduces stomach acid, similar to esomeprazole)
What this could lead to
If successful, keverprazan could offer a new treatment option for first-time H. pylori infections, potentially improving eradication rates.
What could go wrong
This is a completed trial, but results are not yet published. The study is relatively small (264 participants) and only includes first-time infections, so findings may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

264 people

The number who actually took part.

Started

Mar 2025

Finished

Nov 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria * 1)18\~65 years old, gender is not limited; * 2\) H. pylori infection was diagnosed by urea breath test; * 3\) Did not receive H. pylori eradication therapy; * 4\) Informed and consented to participate in this study. Exclusion Criteria: * 1\) Have serious systemic diseases, major organs such as heart, lung, brain diseases, liver and kidney insufficiency, malignant tumors or other diseases; * 2\) Active peptic ulcer with bleeding, perforation, obstruction, cancer and other complications; And subjects with a past or current history of Zolling-Ellison syndrome's disorders; * 3\) Allergic history of penicillin and regimen related drugs; * 4\) Excessive acid-suppressing drugs, such as proton pump inhibitors, potassium competitive acid blockers, histamine H2 receptor antagonists, etc. were used within 2 weeks before enrollment, or antibiotics were used 4 weeks before enrollment; * 5\) Pregnant or lactating women; * 6\) Other participants were deemed unsuitable by the researchers.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Helicobacter pylori are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Helicobacter pylori infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Helicobacter pylori

Contacts and locations

Locations

  • KeyLabGIDiseasesGansu

    Lanzhou, Gansu, 730000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.